Now only 10 weeks out from being the second country in the world to legalize cannabis, the news isn’t taking a break.
Don’t worry, neither are we. The ‘Bis has rounded up the five top news stories breaking this week. Aurora is setting its sights on Alberta with multiple retail opening, Canopy wants to see if CBD can help your pet and more. Here is The ‘Bis weekly news update for August 4 to 11, 2018.
Aurora has entered into an exclusive partnership with Alberta-based liquor retailer Alcanna to open up a fleet of stores across the province.
The license agreement gives Alcanna exclusive rights to open retail cannabis stores under the brand name “Aurora” across Canada.
Alcanna is the biggest private sector liquor retailer in Canada with 229 retail outlets is western Canada and Alaska.
“We have collaborated on store design and layout to ensure the ultimate customer-focused experience, based on a broad selection of products that we anticipate will resonate strongly with the adult consumer use market,” Aurora CEO Terry Booth said in a press release.
There are 37 stores anticipated to open on October 17 in Alberta, the maximum number permitted to a single operator under provincial regulations in year one of legalized adult consumer use.
“We are excited to operationalize this vision, and execute rapidly in Alberta, and across Canada, wherever we are permitted to do so,” said James Burns, CEO of Alcanna.
“We have deep capabilities that will enable us to rapidly develop a large network of well-located cannabis stores, delivering a unique customer experience.”
Canopy Health announced this week that approval has been received from the Veterinary Drug Directorate of Health Canada to research the effectiveness of cannabidiol (CBD) to treat anxiety in certain animals.
The research will be conducted by Canopy Animal Health (CAH), a division of Canopy Health which focuses on developing cannabis-based healthcare products for companion animals.
The approval comes in the form of a No Objection Letter for the use of a proprietary CBD enriched oil formulation, previously administered in preclinical dosing and safety studies, as a potential therapy for anxiety. The CBD formulation will be produced by Canopy Growth in its GMP-certified production facility in Smiths Falls, Ontario.
“Our passion to create safe and effective products for animals is driven by the love we share for our pets,” commented Marc Wayne, Managing Director, Canopy Health. “The use of natural-occurring cannabinoids as a therapy for companion animals is a logical new forefront of medical discovery and the research we are working on at CAH is world leading.
“These trial approvals mark a significant milestone on the journey of making cannabis-based drugs accepted and recommended by veterinarians.”
Despite much speculation in the media (including our own news round-up last week), that there was an announcement coming that would offically make Ontario cannabis sales private.
However, instead of clarification, there was only the announcement relating to the “buck-a-beer” program. No further announcements relating to cannabis have been made.
This comes after a Global News report that indicates the Ontario Cannabis Store has placed no orders for any cannabis products from government approved producers.
Cannabis company the Cronos Group has sealed a five-year deal to supply a US cannabis oil company’s forthcoming production facility in Canada.
Cronos Group will supply Oregon firm Cura’s Canadian arm with at least 20,000 kilograms of pot each year. It will select and cultivate strains for Cura’s CBD oil extraction operation.
The deal was struck after Cura announced plans to build a proprietary facility in British Columbia.
Doctors in Canada want to see the medical marijuana system phased out once legalization happens later this year, says a Canadian Medical Association vice-president.
“The medical profession, as a whole, has really struggled with the whole concept of medical cannabis. There’s definitely some physicians who feel comfortable in that area but most don’t,” Dr. Jeff Blackmer, vice-president of medical professionalism for the Canadian Medical Association, told CBC Calgary earlier this week.
“And [that is] primarily because of the lack of evidence, the lack of scientific studies showing it actually works, the lack of knowledge around dosing and interactions with other medications — all these types of things. Our recommendation was that once it is legalized, that there really is no reason for a separate medical system.”
Blackmer, cites both the lack of education for doctors and the absence of conclusive clinical testing as the primary reason for this.